VERAXA Biotech (NASDAQ: VRXA) Advances BiTAC(R)-TCE Development with Positive Regulatory Feedback from Germany IBN.ai

The company has received Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) supporting the proposed development strategy for its lead BiTAC(R)-TCE program.
The regulatory feedback provides early guidance on the company’s biological rationale, safety assessments, and non-clinical development plan, for its novel therapeutic platform.
VERAXA believes the advice helps reduce development uncertainty by providing greater clarity before advancing toward clinical studies.
The company’s lead BiTAC(R)-TCE candidate previously generated encouraging preclinical data presented at the 2026 American Association for Cancer Research (“AACR”) Annual Meeting.
VERAXA continues to build a diversified oncology pipeline that includes bispecific T-cell engagers, antibody-drug conjugates (“ADCs”) and other engineered antibody formats.
The latest regulatory milestone follows continued progress in manufacturing and development as the company advances next-generation antibody therapeutics for cancer.

VERAXA Biotech (NASDAQ: VRXA), an emerging leader in designing novel cancer therapies, has taken another step in the development of its proprietary BiTAC(R)-TCE platform after receiving Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”), providing regulatory feedback on the biological rationale and proposed non-clinical development strategy for its lead therapeutic program. The announcement, released on July 20, signals progress as the biotechnology company prepares its most advanced BiTAC(R)-TCE candidate for future clinical development (https://ibn.fm/zBiDU).

Scientific Advice procedures allow drug developers to consult with regulatory experts before clinical trials begin, helping companies align their development strategies with regulatory expectations regarding safety, tolerability and…